•Orthocell granted ethical approval for a clinical study using Celgro™ collagen membrane for the treatment of bone defects around dental implants
• The study is to demonstrate that Celgro™ can be used as a barrier membrane to allow bone growth without competition from other connective tissue
• Performed in collaboration with leading West Australian maxillofacial surgeon Dr Brent Allan and the University of Western Australia
Perth, Australia; 9 th March 2015 Regenerative medicine company Orthocell has been granted ethical approval by St John of God Hospital Subiaco for a pilot clinical study examining the safety and effectiveness of its CelgroTM collagen scaffold to help repair bone loss around dental implants. There are more than 3 million dental implant procedures carried out in US every year and that number is growing by 500,000 a year. This represents a significant potential market opportunity for Celgro™.
CelgroTM represents a breakthrough in regenerative medicine that is developed and manufactured in Australia to address unmet clinical needs in the general surgical and orthopaedic soft tissue repair market around the world. The global orthopaedic soft tissue repair market was worth approximately $US7 billion in 2013 and is expected to be worth more than $US10 billion by 2020.
Orthocell received ethics approval to conduct the study from the Australian-wide St John of God hospital group. The study will involve 15 patients and be carried out in Perth by leading West Australian oral and maxillofacial surgeons Dr Brent Allan. The University of Western Australia is also collaborating on the study.
Orthocell Managing Director Paul Anderson said: “This pilot study is an important step in the development of Celgro™ and further demonstrates that Celgro™ is a very valuable product in the large and growing regenerative medicine market.”
Guided bone regeneration is the main standard of care to support new bone formation at dental implant sites. A barrier membrane is placed over the bone defect to allow the ingrowth of bone without competition from gum tissue. CelgroTM is unique from other membrane barriers currently being used in surgical procedures. CelgroTM is completely pure and free from cells and reactive DNA and has been shown to promote tissue ingrowth and repair. It has been developed for use in surgical applications such as tendon repair, dental applications and restructuring of damaged soft tissue in the body. The pilot study is due to begin in Q2 2015
About Orthocell Limited
Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (OrthoATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.
For more information, please contact: General enquiries
Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au
Media enquiries
Gavin Lower Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au
Investor Relations
Rebecca Wilson Buchan Consulting
P: 0417 382 391
E: rwilson@buchanwe.com.au
Help employers find you! Check out all the jobs and post your resume.
• The study is to demonstrate that Celgro™ can be used as a barrier membrane to allow bone growth without competition from other connective tissue
• Performed in collaboration with leading West Australian maxillofacial surgeon Dr Brent Allan and the University of Western Australia
Perth, Australia; 9 th March 2015 Regenerative medicine company Orthocell has been granted ethical approval by St John of God Hospital Subiaco for a pilot clinical study examining the safety and effectiveness of its CelgroTM collagen scaffold to help repair bone loss around dental implants. There are more than 3 million dental implant procedures carried out in US every year and that number is growing by 500,000 a year. This represents a significant potential market opportunity for Celgro™.
CelgroTM represents a breakthrough in regenerative medicine that is developed and manufactured in Australia to address unmet clinical needs in the general surgical and orthopaedic soft tissue repair market around the world. The global orthopaedic soft tissue repair market was worth approximately $US7 billion in 2013 and is expected to be worth more than $US10 billion by 2020.
Orthocell received ethics approval to conduct the study from the Australian-wide St John of God hospital group. The study will involve 15 patients and be carried out in Perth by leading West Australian oral and maxillofacial surgeons Dr Brent Allan. The University of Western Australia is also collaborating on the study.
Orthocell Managing Director Paul Anderson said: “This pilot study is an important step in the development of Celgro™ and further demonstrates that Celgro™ is a very valuable product in the large and growing regenerative medicine market.”
Guided bone regeneration is the main standard of care to support new bone formation at dental implant sites. A barrier membrane is placed over the bone defect to allow the ingrowth of bone without competition from gum tissue. CelgroTM is unique from other membrane barriers currently being used in surgical procedures. CelgroTM is completely pure and free from cells and reactive DNA and has been shown to promote tissue ingrowth and repair. It has been developed for use in surgical applications such as tendon repair, dental applications and restructuring of damaged soft tissue in the body. The pilot study is due to begin in Q2 2015
About Orthocell Limited
Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (OrthoATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.
For more information, please contact: General enquiries
Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au
Media enquiries
Gavin Lower Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au
Investor Relations
Rebecca Wilson Buchan Consulting
P: 0417 382 391
E: rwilson@buchanwe.com.au
Help employers find you! Check out all the jobs and post your resume.
